Auto saved by Logseq

journals/2024_12_05.md

@@ -27,6 +27,7 @@
 			- **WP1: Regulatory aspects.**
 			- **WP5: PQ at WHO**
 			- **WP1. Interim report**
+			- **WP2. REALISE cliinical trial**
 			-
 		- ### Notas
 			- AK: We wont get everythinig clear before june 2026, therefore the non cost extension will be starting to discuss with Ana Duarte (project officer at EDCTP). For all to be clear, all info that pertains to WP3,4 and 5. All info that is needed should be ready by july august 2025. The main reason is to have wp2 finishing al the activities related to the visit on month eleven and everything related to closing the clinical trial. For how long? 6 or 12 months?
@@ -52,6 +53,7 @@
 			- AK: They may request additional data. We have started to revise a new version of the systematic review of high dose ivm during the pandemic. Registered in PROSPERO. When any news brought here. That would be useful
 			- AB: We've missed the EoI deadline. I didn't know until recently that ALB and IVM arae in the EML, and ALB does specific mention of combination with IVM. It makes it a lot easier than other medicines that have to make from scratch the case that they should be added. We're quite a few steps along the way.
 			- CV: Interim report, add it to the word document
+			- AL: Protocol 2.0 we received full approval from ERC and FDA. Kenya we have IRB, waiting for PPB.
 		- ### Decisiones
 			- TODO Añadir el interim report al documento de Word  STOP2030
 			  SCHEDULED: <2024-12-09 Mon>